Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Diabetic Neuropathic Pain-Pipeline Insights, 2015 - A DelveInsight’s ReportDelveInsight, the leading market research and consulting company has added a new report “Diabetic Neuropathic Pain-Pipeline Insights, 2015” to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight.
By: DelveInsight The report “Diabetic Neuropathic Pain-Pipeline Insights, 2015” provides client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes: • The information of around 55 pipeline drugs with 40+ companies involved in drug development. There are 2 drugs in Phase III, 10 in Phase II, 3 in Phase I, 6 in pre-clinical , 1 discoverey, 12 discontinued and 21 dormant drugs. • Mirogabalin developed by Daichi Sankyo and Clonidine developed by Bio Delivery Sciences International is under Phase III clinical trial. • R&D activities and technologies used along with the pipeline molecules in development • Stages of development of pipeline molecules. • Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. • Information related to collaborations, in-licensing and out-licensing deals. DelveInsight’ DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License. For more information on Pipeline Insight Reports, email atinfo@delveInsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making, identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|